GlassScriptPhysician profile
Heather M Bennett
NPI 1215448832
$5,077.78
in general payments reported to CMS, 2019-2025
44 companies · $1,540 in 2025
The $1,540 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $254 · 2022: $1,004 · 2023: $1,022 · 2024: $1,259 · 2025: $1,540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,541 · Education: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,540.63 |
| Education | $279.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $575.19 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $352.01 | 2022-2025 | Keytruda, Welireg, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $302.12 | 2021-2023 | Opdivo |
| Pharmacyclics LLC, An Abbvie Company | $301.43 | 2022-2023 | Imbruvica, Epkinly |
| Daiichi Sankyo INC. | $244.09 | 2022-2025 | Enhertu, Datroway, Injectafer |
| Abbvie INC. | $235.18 | 2024-2025 | |
| Pfizer INC. | $228.10 | 2022-2025 | |
| Gilead Sciences, INC. | $215.56 | 2023-2025 | Trodelvy |
| Janssen Biotech, INC. | $181.65 | 2022-2025 | Rybrevant, Tecvayli, Talvey |
| Astrazeneca Pharmaceuticals LP | $167.27 | 2023-2025 | Imfinzi, Enhertu, Calquence |
| Amgen INC. | $167.19 | 2022-2023 | Nplate, Xgeva, Lumakras |
| Celgene Corporation | $167.03 | 2022-2025 | Reblozyl, Breyanzi |
| Alexion Pharmaceuticals, INC. | $166.63 | 2024-2025 | Soliris, Ultomiris |
| Genzyme Corporation | $150.10 | 2022-2025 | |
| Incyte Corporation | $137.01 | 2023-2025 | Jakafi, Monjuvi, Zynyz |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $133.77 | 2021-2025 | Libtayo, Lynozyfic |
| Lilly USA, LLC | $123.46 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Genentech USA, INC. | $121.37 | 2023-2024 | Venclexta, Phesgo, Polivy |
| Glaxosmithkline, LLC. | $118.01 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| Eisai INC. | $103.92 | 2022-2025 | |
| Emd Serono, INC. | $81.23 | 2024 | |
| Tersera Therapeutics LLC | $77.73 | 2023-2025 | Zoladex, Xermelo |
| Astellas Pharma US INC | $75.36 | 2023-2024 | Padcev, Xtandi, Xospata |
| Stemline Therapeutics INC. | $73.37 | 2023-2025 | Orserdu |
| Ipsen Biopharmaceuticals, INC | $68.42 | 2023-2025 | Onivyde, Tazverik |
| Takeda Pharmaceuticals U.S.A., INC. | $68.30 | 2022-2025 | Fruzaqla |
| Aveo Pharmaceuticals, INC. | $56.57 | 2023-2025 | Fotivda |
| Jazz Pharmaceuticals INC. | $40.53 | 2021 | |
| Sobi, INC | $31.76 | 2023-2024 | |
| Array Biopharma INC | $31.27 | 2022-2024 | Xalkori, Lorbrena, Braftovi |
| Genmab U.S., INC. | $26.43 | 2025 | Epkinly |
| Tempus Ai, INC | $25.82 | 2025 | Xt Cdx |
| Cumberland Pharmaceuticals, INC. | $24.31 | 2023 | Sancuso |
| Adaptive Biotechnologies Corporation | $23.09 | 2025 | Clonoseq |
| Sun Pharmaceutical Industries INC. | $21.08 | 2024 | |
| Accord Healthcare, INC. | $20.97 | 2025 | |
| Springworks Therapeutics, INC. | $20.25 | 2024 | Ogsiveo |
| Apellis Pharmaceuticals, INC. | $18.45 | 2023 | Empaveli |
| Beigene USA, INC. | $18.24 | 2025 | Brukinsa |
| Rigel Pharmaceuticals, INC. | $18.18 | 2023 | Tavalisse, Rezlidhia |
| Bayer Healthcare Pharmaceuticals INC. | $18.13 | 2022 | |
| Pharmaessentia USA Corporation | $17.60 | 2023 | Besremi |
| Secura Bio, INC. | $15.54 | 2023 | Copiktra |
| Kyowa Kirin, INC. | $14.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.